The Food and Drug Administration (FDA) now requires that all clinical trials for drugs that affect the central nervous system--including psychiatric drugs--are assessed for whether that drug might cause suicidal ideation or behavior. The Institute of Medicine's (IOM) Forum on Neuroscience and Nervous System Disorders hosted a meeting on June 26, 2009, to discuss the FDA's new policy and how to analyze best whether suicidal thoughts predict actual suicidal behavior in the near future.
Table of Contents
|1 Perspectives from the FDA, Academia, and Patients||7-16|
|2 Data Collection and Optimization||17-24|
|3 Data Analysis||25-34|
|4 Partnerships, Opportunities, Collaboration||35-42|
|Appendix A: References||43-50|
|Appendix B: Workshop Agenda||51-60|
|Appendix C: Workshop Attendees||61-64|
|Appendix D: Biographical Sketches of Invited Speakers||65-76|
The National Academies Press and the Transportation Research Board have partnered with Copyright Clearance Center to offer a variety of options for reusing our content. You may request permission to:
For most Academic and Educational uses no royalties will be charged although you are required to obtain a license and comply with the license terms and conditions.
For information on how to request permission to translate our work and for any other rights related query please click here.
For questions about using the Copyright.com service, please contact:
Copyright Clearance Center
22 Rosewood Drive
Danvers, MA 01923
Tel (toll free): 855/239-3415 (select option 1)
Loading stats for CNS Clinical Trials: Suicidality and Data Collection: Workshop Summary...